Journal article icon

Journal article

Minimizing risk of hypomethylating agent failure in patients with higher-risk MDS and practical management recommendations.

Abstract:

In Europe, azacitidine is the only hypomethylating agent approved for the treatment of patients with int-2-/high-risk myelodysplastic syndromes, offering significantly improved survival compared with conventional care. However, not all patients treated with azacitidine respond to treatment, and the vast majority of responders subsequently relapse. Currently, no standard care regimens have been established for patients after failure of azacitidine. Here, we discuss treatment options after loss...

Expand abstract
Publication status:
Published

Actions


Access Document


Authors


Expand authors...
Publisher:
Elsevier Ltd
Journal:
Leukemia research
Volume:
38
Issue:
12
Pages:
1381-1391
Publication date:
2014-09-05
DOI:
EISSN:
1873-5835
ISSN:
0145-2126
URN:
uuid:330a88d2-069a-4497-999c-97100ab85d74
Source identifiers:
493462
Local pid:
pubs:493462

Terms of use


Metrics


Views and Downloads






If you are the owner of this record, you can report an update to it here: Report update to this record

TO TOP